Literature DB >> 16061049

Intermediate versus hard end points in clinical trials on hypertension.

Guido Grassi1.   

Abstract

The main features of randomized clinical trials performed in the field of hypertension treatment are reviewed, based either on the evaluation of clinical events or on the assessment of surrogate outcome measures. The advantages, limitations, and clinical relevance of each approach are highlighted.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16061049     DOI： 10.1007/s11906-005-0028-x

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


  27 in total

Review 1.  Evidence-based medicine and hypertension.

Authors:  J D Swales
Journal:  J Hypertens       Date:  1999-11       Impact factor: 4.844

Review 2.  Evidence-based medicine: an educational instrument or a standard for implementation?

Authors:  G Mancia; A Zanchetti
Journal:  J Hypertens       Date:  1999-11       Impact factor: 4.844

Review 3.  Can randomised trials inform clinical decisions about individual patients?

Authors:  D Mant
Journal:  Lancet       Date:  1999-02-27       Impact factor: 79.321

4.  Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation.

Authors:  Peter M Rothwell
Journal:  Lancet       Date:  2005 Jan 8-14       Impact factor: 79.321

5.  Racial/ethnic disparities in prevalence, treatment, and control of hypertension--United States, 1999-2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2005-01-14       Impact factor: 17.586

6.  Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach.

Authors:  A Zanchetti; G Mancia
Journal:  J Hypertens       Date:  1996-07       Impact factor: 4.844

7.  Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators.

Authors:  J R Hampton; D J van Veldhuisen; F X Kleber; A J Cowley; A Ardia; P Block; A Cortina; L Cserhalmi; F Follath; G Jensen; J Kayanakis; K I Lie; G Mancia; A M Skene
Journal:  Lancet       Date:  1997-04-05       Impact factor: 79.321

8.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

9.  Lack of control of high blood pressure and treatment recommendations in Canada.

Authors:  N Khan; A Chockalingam; N R C Campbell
Journal:  Can J Cardiol       Date:  2002-06       Impact factor: 5.223

Review 10.  Clinical trials and tribulations.

Authors:  Gordon T McInnes
Journal:  Clin Exp Pharmacol Physiol       Date:  2002-11       Impact factor: 2.557
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.